Category: 637-58-1

Dziaduszek, Jerzy published the artcileAnorectal drug products for over-the-counter human use; final monograph, Synthetic Route of 637-58-1, the publication is Federal Register (1990), 55(150), 31776-83, database is CAplus.

Active ingredients and permitted combinations of active ingredients in over-the-counter anorectal products for external or intrarectal administration are given under the Federal Food, Drug, and Cosmetic Act. Classes of active ingredients include anesthetics, vasoconstrictors, protectants, analgesics, antipruritics, astringents, and keratolytics. Labeling of anorectal drug products is also considered.

Federal Register published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C13H8BrIN2O2S, Synthetic Route of 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Flores-Alamo, Marcos published the artcileAnorectal drug products for over-the-counter human use; tentative final monograph, COA of Formula: C17H28ClNO3, the publication is Federal Register (1988), 53(157), 30756-84, database is CAplus.

Components of over-the-counter anorectal products suitable for external (topical) or intrarectal administration and allowed combinations of active ingredients and their labeling are given under the Federal Food, Drug, and Cosmetic Act. Classes of active ingredients include: local anesthetics, vasoconstrictors, protectants, analgesics, anesthetics, antipruritics, astringents, and/or keratolytic agents.

Federal Register published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C12H10BFO3, COA of Formula: C17H28ClNO3.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Papez, Maja published the artcileAnorectal drug products for over-the-counter human use, Formula: C17H28ClNO3, the publication is Federal Register (2003), 68(165), 51167-51170, database is CAplus.

The Food and Drug Administration (FDA) is issuing, under the Federal Food, Drug, and Cosmetic Act, a final rule establishing that any over-the-counter (OTC) drug product containing a combination of hydrocortisone and pramoxine hydrochloride (HCl) for anorectal use is not generally recognized as safe and effective and is misbranded. This combination product is not currently marketed OTC. This final rule discusses data on the combination of hydrocortisone and pramoxine HCl that were still under review when an earlier final rule on OTC anorectal drug products was issued. This rule is part of FDA’s ongoing review of OTC drug products.

Federal Register published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C10H13NO2, Formula: C17H28ClNO3.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Shier, W. Thomas published the artcileInhibition of acyl coenzyme A:lysolecithin acyltransferases by local anesthetics, detergents and inhibitors of cyclic nucleotide phosphodiesterases, HPLC of Formula: 637-58-1, the publication is Biochemical and Biophysical Research Communications (1977), 75(1), 186-93, database is CAplus and MEDLINE.

Acyl coenzyme A:lysolecithin acyltransferase [9027-64-9] activity in microsomal preparations from rat liver, rat heart, and rabbit gastric mucosa was inhibited by a series of tertiary amine local anesthetics, detergents, and some inhibitors of cyclic nucleotide phosphodiesterases. Aspirin [50-78-2] and indomethacin [53-86-1] cause elevated lysolecithin/lecithin ratios in the stomachs of mice after oral administration. Inhibition of acyltransferase activity in microsomal preparations by local anesthetics correlated with reported anesthetic potencies at approx. 1/100 reported therapeutic dosages. In BHK-13 cells acyltransferase activity was inhibited at 1/3 to 1/10 the concentrations that have been reported to cause alterations in the mobility and topog. of cell surface receptors.

Biochemical and Biophysical Research Communications published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C14H10O4S2, HPLC of Formula: 637-58-1.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Schmidt, Andrea C. published the artcileThe Role of Molecular Structure in the Crystal Polymorphism of Local Anesthetic Drugs: Crystal Polymorphism of Local Anesthetic Drugs, Part X, Recommanded Product: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Pharmaceutical Research (2005), 22(12), 2121-2133, database is CAplus and MEDLINE.

This report is the resume of a comprehensive investigation on the solid-state properties and the crystal polymorphism of the structurally homogeneous class of local anesthetic drugs. The goal is to explore the relationship between crystal polymorphism and mol. structural features. A salt form (mostly the hydrochloride) as well as the free base of 24 local anesthetics has been characterized by means of thermomicroscopy, differential scanning calorimetry, pycnometry, Fourier transform IR, Fourier transform Raman, and solid-state NMR spectroscopies, as well as x-ray diffraction methods (single crystal, powder). Based on the thermochem. data, the relative thermodn. stabilities of the different crystal forms of each polymorphic system were evaluated and visualized as semiquant. energy/temperature diagrams. This study is the first step in recognizing relationships between the structure and the solid-state properties within this limited group of active substances with common structural elements. The results clearly show that there are certain relationships, but, to understand the phenomenol. behavior in more detail on a mol. level, more structural information must be collected and analyzed by computational methods.

Pharmaceutical Research published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Recommanded Product: 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Ida, Tadao published the artcileProtective coating. II. Amino derivatives of saccharides and polyhydric alcohols, Related Products of ethers-buliding-blocks, the publication is Yakugaku Zasshi (1958), 501-4, database is CAplus.

cf. C.A. 52, 9519h. Amine derivatives (I) of sugars and polyhydric alcs. were prepared and their utility as the protective coating agents was examined The I were prepared either by refluxing glucose, xylose, or lactose with various amines in alc. or by the application of various amines to sucrose, dextrin, and mannitol p-toluenesulfonates. Among the I tested, dodecylamine N-lactoside and N-xyloside were the only ones that possessed resistance to water, solubility in gastric juice, and ability to form a membrane. These were used as a coating on starch-lactose tablets and their resistance to water and solubility in gastric juice were tested by measuring the duration of disintegration in distilled water and simulated gastric juice. Both derivatives were found to be excellent agents for protective coating.

Yakugaku Zasshi published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Blanpin, Odette published the artcileThe local-anesthetic action of pramoxine hydrochloride (tronothane, Related Products of ethers-buliding-blocks, the publication is Anesthesie, Analgesie, Reanimation (1957), 225-31, database is CAplus.

Pramoxine (or tronothane) is p-butoxyphenyl morpholinopropyl ether-HCl (I). Its pharmacol. properties and toxicity are reported. L.D.₅₀ (intravenous injection into caudal vein of the mouse) 132 mg./kg.; L.D._min. (slow intravenous infusion in guinea pigs) 108.7 ± 2.3 mg./kg.; L.D.₅₀ (subcutaneous injection into the mouse) 1.47 g./kg. A 1% solution of I was used to determine its local tolerance (in the eye of a rabbit) and its effectiveness as a local anesthetic (also on rabbits). I was found to be 3.6 times as effective as cocaine-HCl when used as a local anesthetic on the skin surface and 1.5 times as effective as procaine-HCl (II) in infiltration tests on guinea pigs. In tests determining the reduction of the excitability of a frog muscle preparation (sciatic nerve to the gastrocnemius muscle in Ringer solution, pH 6) a 0.10% solution of I had about the same effect as a 0.01% solution of II. I is, therefore, an excellent surface anesthetic, but its use in eye surgery must be rigorously avoided because of its property of producing necrosis of the mucous membrane and muscle fibers.

Anesthesie, Analgesie, Reanimation published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Related Products of ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Adriani, John published the artcileThe comparative potency and effectiveness of topical anesthetics in man, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Clinical Pharmacology & Therapeutics (New York, NY, United States) (1964), 49-62, database is CAplus and MEDLINE.

A technique with the use of elec. stimulation was developed. The tip of the tongue is the most sensitive area in the body to this type of stimulation. Over 40 drugs with topical activity were studied with the tip of the tongue as the test site. The most potent and effective compounds are tetracaine, cocaine, dibucaine, lidocaine, and dyclonine (I). With exception of I, these are toxic systemically if used in excess. The addition of vasoconstrictors, detergents, demulcents, cations, hyaluronidase, and other often-suggested potentiating agents does extend the period of activity.

Clinical Pharmacology & Therapeutics (New York, NY, United States) published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C17H28ClNO3, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Vafai, Yassaman published the artcilePrenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status, Category: ethers-buliding-blocks, the publication is Journal of Maternal-Fetal & Neonatal Medicine, database is CAplus and MEDLINE.

The association between obesity (body mass index (BMI) ≥ 30 kg/m2) and pattern of medication use during pregnancy in the United States is not well-studied. Higher pre-pregnancy BMI may be associated with increases or decreases in medication use across pregnancy as symptoms (e.g. reflux) or comorbidities (e.g. gestational diabetes) requiring treatment that may be associated with higher BMI could also change with advancing gestation. To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status. In a secondary data anal. of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clin. sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery. In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19-29.9 kg/m2), more than 70% of pregnant women (77% of women with and 73% of women without obesity) reported taking at least one medication during pregnancy, resp. (adjusted risk ratio (aRR)=1.10, 95% confidence interval (CI)=1.01, 1.20), with 81% reporting two and 69% reporting three or more. A total of 17 classes of medications were identified. Among medication classes consumed by at least 5% of all women, the only class that differed between women with and without obesity was hormones and synthetic substitutes (including steroids, progesterone, diabetes, and thyroid medications) in which women with obesity took more medications (11 vs. 5%, aRR = 1.9, 95% CI = 1.38, 2.61) compared to women without obesity. Within this class, a higher percentage of women with obesity took diabetes medications (2.3 vs. 0.7%) and progesterone (3.4 vs. 1.3%) than their non-obese counterparts. Similar percentages of women with and without obesity reported consuming medications in the remaining medication classes including central nervous system agents (50 and 46%), gastrointestinal drugs (43 and 40%), anti-infective agents (23 and 21%), antihistamines (20 and 17%), autonomic drugs (10 and 9%), and respiratory tract agents (7 and 6%), resp. (p > 0.05 for all adjusted comparisons). There were no differences in medication use by obesity status across gestation. Since the study exclusion criteria limited the non-obese group to women without thyroid disease, in a sensitivity anal. we excluded all women who reported thyroid medication intake and still a higher proportion of women with obesity took the hormones and synthetic substitutes class compared to women without obesity. Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.

Journal of Maternal-Fetal & Neonatal Medicine published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C19H14N2, Category: ethers-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem

Thompson, W. E. published the artcileIdentification of primary, secondary, and tertiary pharmaceutical amines by the infrared spectra of their salts, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, the publication is Journal of Pharmaceutical Sciences (1965), 54(12), 1819-21, database is CAplus.

The spectra of 80 pharmaceutically active amine salts have been analyzed in the range of 4000-2000 cm.^-1 The amine salts have characteristic absorption bands in this region. The wave numbers at which these absorption bands occur are specific for each given class of amine. Spectra and structure correlations and assignments of these bands are given and discussed.

Journal of Pharmaceutical Sciences published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C14H12O2, Safety of 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride.

Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem